Exportin(g) precision oncology beyond genomics with XPO1 inhibition

Mohamed A. Gouda; Vivek Subbiah

doi:10.1016/j.medj.2022.10.005

Exportin(g) precision oncology beyond genomics with XPO1 inhibition

Mohamed A. Gouda, Vivek Subbiah

Investigational Cancer Therapeutics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

We urgently need to identify new druggable targets for pediatric cancers. Coutinho et al.¹ identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.

Original language	English (US)
Pages (from-to)	730-732
Number of pages	3
Journal	Med
Volume	3
Issue number	11
DOIs	https://doi.org/10.1016/j.medj.2022.10.005
State	Published - Nov 11 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.medj.2022.10.005

Cite this

@article{e26eae3fbb424542b5d20e86540467da,

title = "Exportin(g) precision oncology beyond genomics with XPO1 inhibition",

abstract = "We urgently need to identify new druggable targets for pediatric cancers. Coutinho et al.1 identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.",

author = "Gouda, {Mohamed A.} and Vivek Subbiah",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = nov,

day = "11",

doi = "10.1016/j.medj.2022.10.005",

language = "English (US)",

volume = "3",

pages = "730--732",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Exportin(g) precision oncology beyond genomics with XPO1 inhibition

AU - Gouda, Mohamed A.

AU - Subbiah, Vivek

PY - 2022/11/11

Y1 - 2022/11/11

N2 - We urgently need to identify new druggable targets for pediatric cancers. Coutinho et al.1 identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.

AB - We urgently need to identify new druggable targets for pediatric cancers. Coutinho et al.1 identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.

UR - http://www.scopus.com/inward/record.url?scp=85141696446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141696446&partnerID=8YFLogxK

U2 - 10.1016/j.medj.2022.10.005

DO - 10.1016/j.medj.2022.10.005

M3 - Comment/debate

C2 - 36370692

AN - SCOPUS:85141696446

SN - 2666-6359

VL - 3

SP - 730

EP - 732

JO - Med

JF - Med

IS - 11

ER -

Exportin(g) precision oncology beyond genomics with XPO1 inhibition

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this